ナノ材料ベースのアジュバントワクチンの世界市場レポート2026-2032

QY Research > レポート一覧 > 薬品及びサプリメント > ナノ材料ベースのアジュバントワクチンの世界市場レポート2026-2032

英文タイトル： Global Nanomaterial-Based Adjuvants Vaccine Market Research Report 2026

レポートID：1613175
発表時期：2026-01-05
訪問回数：267
ページ数：115
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：110
レポートカテゴリ：薬品及びサプリメント

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

世界のナノ材料ベースのアジュバントワクチン市場は、2025年に355310百万米ドルと算定されており、2026年には386100百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）9.6%で推移し、2032年には670310百万米ドルに達すると予測されています。

本レポートは、ナノ材料ベースのアジュバントワクチンメーカー、新規参入企業、および業界バリューチェーン全体の企業に対し、市場全体およびサブセグメント別の収益、生産量、平均価格に関する情報を、企業別、タイプ別、用途別、地域別に提供します。
世界のナノ材料ベースのアジュバントワクチン市場について、定量的・定性的分析を交えた包括的な概観を提供し、企業関係者が成長戦略の策定、競争環境の評価、現行市場における自社の位置付けの分析、ナノ材料ベースのアジュバントワクチンに関する情報に基づいたビジネス判断を行うことを支援します。ナノ材料ベースのアジュバントワクチン市場の規模、推定値及び予測値の観点から提示し、2025年を基準年として、2021年から2032年までの過去データ及び予測データを収録しております。

報告対象範囲
売上高・数量予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology

タイプ別
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others

用途別
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others

製品カテゴリー

市場セグメント

地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
本レポートは、世界のナノ材料ベースのアジュバントワクチン市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、企業別の市場規模も提供されます。より深い洞察を得るため、競争環境、主要競合他社、それぞれの市場順位をプロファイリングし、技術動向や新製品開発についても論じております。

本レポートの構成
第1章：ナノ材料ベースのアジュバントワクチンの定義および調査範囲を明確化し、市場セグメント（タイプ別、用途別など）の概要を提示します。各セグメントの市場規模と将来の成長可能性を網羅し、現在の市場状況の概要を提供するとともに、短期・中期・長期の発展トレンドを分析します
第2章：ナノ材料ベースのアジュバントワクチンメーカーの競争環境について、価格、生産量、価値ベースの市場シェア、最新の開発計画、合併・買収情報を含め詳細に分析します
第3章：ナノ材料ベースのアジュバントワクチンの生産量／生産高および価値を地域・国別に検証し、今後6年間の各地域の市場規模と成長可能性について定量的な評価を提供します
第4章：地域および国レベルでのナノ材料ベースのアジュバントワクチンの消費動向を分析します。各地域および主要国における市場規模と成長可能性を定量化し、市場開発状況、見通し、対応可能な市場規模、国内生産量を概説します
第5章：ナノ材料ベースのアジュバントワクチンに基づくタイプ別市場セグメントの構造を整理し、各セグメントの市場規模と成長ポテンシャルを明確化することで、企業・投資家によるブルーオーシャン機会の発見を支援します
第6章：用途別にナノ材料ベースのアジュバントワクチンの市場セグメントを整理し、各分野の市場規模、成長ポテンシャル、需要拡大余地を提示することで、下流市場における有望な参入機会や競争優位の確立に向けた判断材料を提供します
第7章：ナノ材料ベースのアジュバントワクチンの主要プレイヤーを分析し、主要企業の基本情報（製品生産量／生産高、価値、価格、粗利益率、製品ポートフォリオ／新製品導入、最近の動向）を詳細に説明します
第8章：ナノ材料ベースのアジュバントワクチンの上流および下流セグメントを含む業界バリューチェーンをレビューします
第9章：ナノ材料ベースのアジュバントワクチン市場の動向と最新トレンドについて議論します。これには、メーカーにとっての推進要因、制約要因、課題、リスク、米国関税、関連政策分析が含まれます
第10章：主な調査結果と結論をまとめます
第11章：付録

Description

The global Nanomaterial-Based Adjuvants Vaccine market was valued at US$ 355310 million in 2025 and is anticipated to reach US$ 670310 million by 2032, at a CAGR of 9.6% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Nanomaterial-Based Adjuvants Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Nanoparticles (NPs) can act as adjuvants for vaccines, hence they are referred to as a nano-adjuvant (NA). NPs can either encapsulate or adsorb the vaccine antigen or DNA in an appropriate formulation, thus increasing stability, cellular uptake, and immunogenicity.

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Technological advancements in nanomaterial-based adjuvants vaccines are an important factor driving market development. Nano-adjuvants have the advantages of good biocompatibility, biological targeting, sustained release, safety and high efficiency, and can significantly improve the immunogenicity and protective effect of vaccines. With the continuous development and application of nanotechnology, the types and performance of nanomaterial-based adjuvants vaccines will be further improved to meet the needs of more disease prevention. As the market continues to expand and potential competitors join, competition in the nanomaterial-based adjuvants vaccines market will become more intense. Overall, the nanomaterial-based adjuvants vaccines market has broad prospects. With the advancement of technology and the increase in market demand, the market size is expected to continue to grow in the next few years.

This report delivers a comprehensive overview of the global Nanomaterial-Based Adjuvants Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nanomaterial-Based Adjuvants Vaccine. The Nanomaterial-Based Adjuvants Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Nanomaterial-Based Adjuvants Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Nanomaterial-Based Adjuvants Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation
By Company
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Jiangsu Recbio Technology

Segment by Type
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others

by Application
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others

Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Nanomaterial-Based Adjuvants Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Nanomaterial-Based Adjuvants Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

Table of Contents

1 Nanomaterial-Based Adjuvants Vaccine Market Overview
1.1 Product Definition
1.2 Nanomaterial-Based Adjuvants Vaccine by Type
1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Aluminium Hydroxides
1.2.3 Aluminium Phosphate
1.2.4 Lipidosome
1.2.5 Others
1.3 Nanomaterial-Based Adjuvants Vaccine by Application
1.3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Pneumococcus
1.3.3 Human Papilloma Virus
1.3.4 DTaP
1.3.5 Viral Hepatitis TypeA
1.3.6 Viral Hepatitis TypeB
1.3.7 SARS-CoV-2
1.3.8 Others
1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts
1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue 2021–2032
1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales 2021–2032
1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations

2 Nanomaterial-Based Adjuvants Vaccine Market Competition by Manufacturers
2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Entry into the Industry
2.8 Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation and Trends
2.8.1 Global Nanomaterial-Based Adjuvants Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue
2.8.3 Global Nanomaterial-Based Adjuvants Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Nanomaterial-Based Adjuvants Vaccine Market Scenario by Region
3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021–2032
3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021–2026
3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2027–2032
3.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021–2032
3.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021–2026
3.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2027–2032
3.4 North America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.4.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.4.3 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.5.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.5.3 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.7.1 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE

4 Segment by Type
4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021–2032)
4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021–2026)
4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2027–2032)
4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021–2032)
4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021–2026)
4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2027–2032)
4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2021–2032)

5 Segment by Application
5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021–2032)
5.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021–2026)
5.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2027–2032)
5.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021–2032)
5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021–2026)
5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2027–2032)
5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2021–2032)

6 Key Companies Profiled
6.1 Emergent BioSolutions
6.1.1 Emergent BioSolutions Company Information
6.1.2 Emergent BioSolutions Description and Business Overview
6.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.1.5 Emergent BioSolutions Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 GlaxoSmithKline Biologicals
6.3.1 GlaxoSmithKline Biologicals Company Information
6.3.2 GlaxoSmithKline Biologicals Description and Business Overview
6.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Moderna
6.7.1 Moderna Company Information
6.7.2 Moderna Description and Business Overview
6.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.7.5 Moderna Recent Developments/Updates
6.8 Jiangsu Recbio Technology
6.8.1 Jiangsu Recbio Technology Company Information
6.8.2 Jiangsu Recbio Technology Description and Business Overview
6.8.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.8.5 Jiangsu Recbio Technology Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis
7.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain Analysis
7.2 Nanomaterial-Based Adjuvants Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process Analysis
7.4 Nanomaterial-Based Adjuvants Vaccine Sales and Marketing
7.4.1 Nanomaterial-Based Adjuvants Vaccine Sales Channels
7.4.2 Nanomaterial-Based Adjuvants Vaccine Distributors
7.5 Nanomaterial-Based Adjuvants Vaccine Customer Analysis

8 Nanomaterial-Based Adjuvants Vaccine Market Dynamics
8.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends
8.2 Nanomaterial-Based Adjuvants Vaccine Market Drivers
8.3 Nanomaterial-Based Adjuvants Vaccine Market Challenges
8.4 Nanomaterial-Based Adjuvants Vaccine Market Restraints
8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
 Table 5. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Types and Applications
 Table 12. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Nanomaterial-Based Adjuvants Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nanomaterial-Based Adjuvants Vaccine Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
 Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2026)
 Table 19. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
 Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2027–2032)
 Table 21. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2026)
 Table 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2027–2032)
 Table 25. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
 Table 27. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
 Table 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
 Table 32. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
 Table 33. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
 Table 37. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
 Table 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
 Table 42. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
 Table 43. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
 Table 47. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
 Table 48. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2021–2026)
 Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2027–2032)
 Table 52. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021–2026)
 Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2027–2032)
 Table 54. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021–2026)
 Table 57. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2027–2032)
 Table 58. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2026)
 Table 59. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2027–2032)
 Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2021–2026)
 Table 61. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2027–2032)
 Table 62. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021–2026)
 Table 63. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2027–2032)
 Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021–2026)
 Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2027–2032)
 Table 68. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2026)
 Table 69. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2027–2032)
 Table 70. Emergent BioSolutions Company Information
 Table 71. Emergent BioSolutions Description and Business Overview
 Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 73. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product
 Table 74. Emergent BioSolutions Recent Developments/Updates
 Table 75. Sanofi Company Information
 Table 76. Sanofi Description and Business Overview
 Table 77. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 78. Sanofi Nanomaterial-Based Adjuvants Vaccine Product
 Table 79. Sanofi Recent Developments/Updates
 Table 80. GlaxoSmithKline Biologicals Company Information
 Table 81. GlaxoSmithKline Biologicals Description and Business Overview
 Table 82. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 83. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product
 Table 84. GlaxoSmithKline Biologicals Recent Developments/Updates
 Table 85. Merck Company Information
 Table 86. Merck Description and Business Overview
 Table 87. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 88. Merck Nanomaterial-Based Adjuvants Vaccine Product
 Table 89. Merck Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 93. Pfizer Nanomaterial-Based Adjuvants Vaccine Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 98. Novartis Nanomaterial-Based Adjuvants Vaccine Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. Moderna Company Information
 Table 101. Moderna Description and Business Overview
 Table 102. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 103. Moderna Nanomaterial-Based Adjuvants Vaccine Product
 Table 104. Moderna Recent Developments/Updates
 Table 105. Jiangsu Recbio Technology Company Information
 Table 106. Jiangsu Recbio Technology Description and Business Overview
 Table 107. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 108. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product
 Table 109. Jiangsu Recbio Technology Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Nanomaterial-Based Adjuvants Vaccine Distributors List
 Table 113. Nanomaterial-Based Adjuvants Vaccine Customers List
 Table 114. Nanomaterial-Based Adjuvants Vaccine Market Trends
 Table 115. Nanomaterial-Based Adjuvants Vaccine Market Drivers
 Table 116. Nanomaterial-Based Adjuvants Vaccine Market Challenges
 Table 117. Nanomaterial-Based Adjuvants Vaccine Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Nanomaterial-Based Adjuvants Vaccine
 Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Type: 2025 & 2032
 Figure 4. Aluminium Hydroxides Product Picture
 Figure 5. Aluminium Phosphate Product Picture
 Figure 6. Lipidosome Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2021–2032
 Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Application: 2025 & 2032
 Figure 10. Pneumococcus
 Figure 11. Human Papilloma Virus
 Figure 12. DTaP
 Figure 13. Viral Hepatitis TypeA
 Figure 14. Viral Hepatitis TypeB
 Figure 15. SARS-CoV-2
 Figure 16. Others
 Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size (US$ Million), 2021–2032
 Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), 2021–2032
 Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose), 2021–2032
 Figure 21. Nanomaterial-Based Adjuvants Vaccine Report Years Considered
 Figure 22. Nanomaterial-Based Adjuvants Vaccine Sales Share by Manufacturers in 2025
 Figure 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers in 2025
 Figure 24. Top 5 and Top 10 Global Nanomaterial-Based Adjuvants Vaccine Players: Market Share by Revenue in Nanomaterial-Based Adjuvants Vaccine in 2025
 Figure 25. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 27. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
 Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
 Figure 29. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
 Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
 Figure 33. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. U.K. Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2032)
 Figure 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2032)
 Figure 40. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. China Taiwan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Indonesia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Thailand Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Malaysia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Latin America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
 Figure 50. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
 Figure 51. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
 Figure 55. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
 Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
 Figure 60. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
 Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2032)
 Figure 62. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
 Figure 63. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
 Figure 64. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2032)
 Figure 65. Nanomaterial-Based Adjuvants Vaccine Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed

以下、関連資料のご紹介